Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

• Egile Nagusiak: Nicolas Hohmann (Egilea), Farastuk Bozorgmehr (Egilea), Petros Christopoulos (Egilea), Gerd Mikus (Egilea), Antje Blank (Egilea), Jürgen Burhenne (Egilea), Michael Thomas (Egilea), Walter E. Haefeli (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2021-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK‐positive non‐small cell lung cancer (NSCLC). When evaluating crizotinib pharmacokinetics (PKs) in patients taking the standard flat oral dose of 250 mg b.i.d., interindividual PK variab...